Beijing Konruns Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (1999)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2016
NCT02916095
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Beijing Konruns Pharmaceutical Co., Ltd. | Guidon Pharmaceutics Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

jincaopian (2 trials)

Drugs in Phase 2 Trials (2)

kc1036 (4 trials)

phenylbutyric acid (1 trial)

Drugs in Phase 1 Trials (4)

exosomes from mesenchymal stem cells (1 trial)

gd-iexo-001 (1 trial)

ipsc (1 trial)

kanitinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 8